| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 7 Aug 2025 | 31 Jul 2025 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30 2025 Outcome of the Board Meeting Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 Acquisition of Dr. RS Patils Ambika Pathology Laboratory (As Per BSE Announcement Dated on:07.08.2025) | ||
| Board Meeting | 13 May 2025 | 5 May 2025 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2025 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31 2025 Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2025 (As Per BSE Announcement Dated on :13.05.2025) | ||
| Board Meeting | 17 Mar 2025 | 17 Mar 2025 |
| Outcome of Board meeting held on Monday, March 17, 2025 | ||
| Board Meeting | 4 Feb 2025 | 29 Jan 2025 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 Unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31, 2024 (As per BSE Announcement Dated on 04/02/2025) | ||
| Board Meeting | 9 Dec 2024 | 4 Dec 2024 |
| Metropolis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/12/2024 ,inter alia, to consider and approve issuance of equity shares of the Company on a preferential basis and Postal ballot notice. Acquisition of the 100% stake in Core Diagnostics Private Limited, India, (Core Diagnostics) from its existing shareholder, Core Diagnostics (Mauritius) Private Limited for a total purchase consideration of INR 246.83 crores to be discharged partly by cash and partly by way of preferential issue and allotment of equity shares of the Company Preferential Issue (As per BSE Announcement Dated on 09/12/2024) | ||
| Board Meeting | 8 Nov 2024 | 30 Oct 2024 |
| Quarterly Results Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 (As per BSE Announcement Dated on 08/11/2024) | ||
The deal includes a deferred payment of ₹1.7 crore, which will be disbursed as per the terms of the business transfer agreement, the company said in a regulatory filing.
The EBITDA margin fell to 18% in Q4 FY25 from 24.2% in Q4 FY24, reflecting a fall in operational efficiency or profitability.
The EBITDA margin was stable at 22.3% and did not change much from the year-ago period.
This is a 100% stake purchase that will be funded through 55% cash and 45% equity swap. It expects completion in 60 days, after shareholders give their nod.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
Here are some of the stocks that may see significant price movement today: Titan Company, HDFC Bank, IndusInd Bank, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
